Insider · CIK 0001821189

Mainolfi Nello

Reports to the SEC for 1 company · WATERTOWN, MA

sec.gov

Transactions

Companies

Filings

CIK

0001821189

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-01	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+30K sh	$2.08	+$62.4K	696,568
2026-10-01	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−3,525 sh	$111.44	−$393K	693,043
2026-10-01	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−5,506 sh	$112.42	−$619K	687,537
2026-10-01	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−4,876 sh	$113.24	−$552K	682,661
2026-10-01	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−7,601 sh	$114.43	−$870K	675,060
2026-10-01	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−8,230 sh	$115.40	−$950K	666,830
2026-10-01	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−262 sh	$116.12	−$30.4K	666,568
2026-10-01	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−30K sh	—	—	60,000
2026-07-07	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+50K sh	$2.08	+$104K	716,568
2026-07-07	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−50K sh	$119.00	−$5.95M	666,568
2026-07-07	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−45.6K sh	—	—	90,000
2026-07-07	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−4,441 sh	—	—	14,284
2026-07-01	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+80K sh	$2.08	+$166K	746,568
2026-07-01	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−1,883 sh	$112.80	−$212K	744,685
2026-07-01	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−6,626 sh	$113.98	−$755K	738,059
2026-07-01	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−24.1K sh	$114.96	−$2.77M	713,954
2026-07-01	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−44.1K sh	$115.69	−$5.1M	669,904
2026-07-01	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−3,336 sh	$116.56	−$389K	666,568
2026-07-01	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−80K sh	—	—	135,559
2026-04-29	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+30K sh	$2.08	+$62.4K	696,195
2026-04-29	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−17K sh	$80.74	−$1.37M	679,190
2026-04-29	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−12.1K sh	$81.70	−$985K	667,131
2026-04-29	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−936 sh	$82.45	−$77.2K	666,195
2026-04-29	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−30K sh	—	—	215,559
2026-03-02	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+215K sh	—	—	215,000
2026-02-25	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+30K sh	$2.08	+$62.4K	696,195
2026-02-25	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−19.8K sh	$89.78	−$1.77M	676,431
2026-02-25	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−5,434 sh	$90.39	−$491K	670,997
2026-02-25	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−3,293 sh	$91.76	−$302K	667,704
2026-02-25	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−1,501 sh	$92.81	−$139K	666,203
2026-02-25	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−8 sh	$93.49	−$747.92	666,195
2026-02-25	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−30K sh	—	—	245,559
2026-01-05	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+3,118 sh	$32.07	+$100K	666,195
2026-01-05	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−3,118 sh	—	—	446,882
2025-12-31	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+30K sh	$2.08	+$62.4K	693,077
2025-12-31	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−24K sh	$77.95	−$1.87M	669,091
2025-12-31	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−6,014 sh	$78.52	−$472K	663,077
2025-12-31	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−30K sh	—	—	275,559
2025-12-17	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+2,595 sh	$38.53	+$100K	663,077
2025-12-17	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−2,595 sh	—	—	272,505
2025-12-08	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+100K sh	$2.08	+$208K	760,482
2025-12-08	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−100K sh	$89.17	−$8.92M	660,482
2025-12-08	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−100K sh	—	—	305,559
2025-10-29	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+30K sh	$2.08	+$62.4K	690,482
2025-10-29	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−1,862 sh	$59.72	−$111K	688,620
2025-10-29	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−24.5K sh	$61.02	−$1.5M	664,109
2025-10-29	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−3,627 sh	$61.46	−$223K	660,482
2025-10-29	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−30K sh	—	—	405,559
2025-09-16	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+30K sh	$2.08	+$62.4K	690,482
2025-09-16	KYMRKymera Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−30K sh	$49.00	−$1.47M	660,482

Recent filings

Accepted (ET)
Oct 14
Mainolfi Nello0001193125-26-410839
SEC(opens sec.gov)
Jul 74
Mainolfi Nello0001193125-26-297817
SEC(opens sec.gov)
Jul 24
Mainolfi Nello0001193125-26-295088
SEC(opens sec.gov)
Apr 294
Mainolfi Nello0001193125-26-192146
SEC(opens sec.gov)

Companies

Kymera Therapeutics, Inc.Director, Chief Executive OfficerKYMR

Address

C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, 4TH FLOOR

WATERTOWN, MA, 02472